Table 3.

Competing risk regression analysis for association of factors with relapse/progression  (N = 483)^a

Characteristic	Strata	Univariate		Multivariable
		HR  (95%CI)	P-value	HR  (95%CI)	P-value
Age  (per 10 years)		1.01  (0 .89, 1.15)	0 .87
Gender	Female	1.0	0 .76
	Male	1.05  (0 .76, 1.45)
Stage	I	1.0	0 .06
	II	1.5  (0 .99, 2.29)
Primary site at diagnosis	Stomach	1.0	<0 .001	1.0	< .001
	Orbit	1.9  (1.13, 3.2)		2.01  (1.07, 3.78)
	Lung	1.81  (1.03, 3.17)		3.16  (1.5, 6.66)
	Skin	2.73  (1.6, 4.65)		2.99  (1.67, 5.35)
	H&N	2.6  (1.34, 5.05)		3.8  (1.92, 7.54)
	Thyroid	0.8  (0 .22, 2.93)		1.23  (0 .34, 4.41)
	Other	1.91  (1.2, 3.06)		2.5  (1.51, 4.14)
IPI risk group	Low  (0–1 points)	1.0	0 .26
	Low-intermediate risk  (2 points)	1.53  (0 .73, 3.18)
B-symptomsa	Not present at diagnosis	1.0	0 .88
	Present	1.08  (0 .4, 2.91)
Initial treatment	RT or ChemoRT	1.0	<0 .001	1.0	< .001
	Surgery	1.22  (0 .83, 1.80)		0 .69  (0 .42, 1.14)
	Chemo or immunotherapy	2.27  (1.19, 4.31)		1.5  (0 .73, 3.09)
	Observation	2.03  (1.19, 3.49)		1.24  (0 .69, 2.24)
	Other	8.27  (4.07, 17)		8.37  (4.39, 15.94)
No. sites at diagnosis	>1 site	1.0	0 .007	1.0	0 .04
	1 site	0.54  (0 .34, 0 .84)		0.58  (0 .35, 0 .97)
Bone marrow biopsy carried out	No	1.0	0 .09
	Yes	0.76  (0 .55, 1.04)

Variables with P-value <0 .2 were selected for multivariable analysis and only variables with P-value < 0 .05 were retained in the final model.

^aUnknown relapse status not included.

HR, hazard ratio; IPI, International Prognostic Index, RT, radiotherapy.